DXCM

DexCom Inc. (DXCM) | Rumor.io

DexCom

DXCM

Attention (50-day avg)0%

Attention rank (50-day avg)#748

Bullish sentiment (50-day avg)93%

Price to earnings ratio34.3

Market capitalization32.7B

Earnings per share2.53

Dividend yield (TTM)—

Revenue (annual)4.7B

Net income (annual)836.3M

Social

What share of all stock conversation is about DXCM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% -0.01	0% 0

Aug 12

DexCom, Inc. (DXCM) has seen a significant increase in its stock price, with a 25.1% rise since insiders were selling three weeks ago.
The stock has cleared the 200-week moving average and is part of a sector that is starting to warm up.
DXCM has printed a new 52-week high and is expected to continue its upward trend, potentially due to an upcoming announcement from CMS, HHS, or another relevant agency.

Generated by AI

Sentiment

Of the messages about DXCM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	16.67% -58.33	33.33% -58.89	80.81% +17.85
Bearish	—	83.33% +58.33	66.67% +58.89	19.19% -17.85

Bullish· Jun 6

DexCom, Inc. is a stock that may rise according to a blogger with accurate analysis and predictions.
Following this blogger's advice can potentially lead to making $6,000 every two weeks.
The blogger has a track record of making money for their followers with their stock recommendations.

Bearish· Apr 21

$DXCM's production quality has been subpar, contributing to its poor performance.
The company's recent leadership changes, specifically the new CEO's public relations efforts, have been ineffective and may be a sign of underlying issues.
$DXCM's stock price has been declining, with weak volume and a lack of interest from investors, suggesting a bearish trend that may continue.

Generated by AI

Topics

Of the messages about DXCM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	64.29%	46.55%	19.09%
Announcements	—	28.57%	25.86%	14.03%
Analysts	—	0%	13.79%	30.71%
Earnings	—	7.14%	1.72%	3.65%
Macro	—	0%	12.07%	32.26%
Controversies	—	0%	0%	0.26%

Earnings· Jul 30

DexCom reported Q2 2026 earnings with revenue of $1.31B, beating estimates by +2% YoY, and adjusted EPS of $0.70, beating estimates by +15% YoY.
The company raised its FY26 revenue guidance to $5.18-$5.25B, with operating margin guided to 23.5-24%, and non-GAAP operating income of $328.3M, beating estimates by +15% YoY.
DexCom's Q2 2026 results showed a +13% YoY revenue growth, with adjusted EBITDA of $421.3M, beating estimates by +9% YoY, and a non-GAAP operating margin of 24.3%, a +590bps YoY increase.

Analysts· Oct 29

Oppenheimer raised DexCom's price target to $625 with an outperform rating.
Multiple analysts, including Canaccord, Piper Sandler, and SVB Leerink, raised DexCom's price target, with some targets exceeding $675.
Analysts at firms such as Morgan Stanley, Jefferies Financial Group, and Robert W. Baird also raised DexCom's price target, with Morgan Stanley maintaining an equal weight rating.

Announcements· Jul 23

NovaRed expanded the Wilmac project to approximately 16,078 hectares through its amended agreement, increasing its land position and future exploration potential.
The company continues to grow its land package through measured expansion and strategic planning, with the latest addition of 5 mineral tenures and 4,573.82 hectares.
NovaRed's amended option agreement marks another major growth of the Wilmac Project, increasing its size to approximately 16,078 hectares and its exploration potential across the project.

Technical Analysis· Jul 29

$DXCM's RSI is currently at 14, considered oversold, and may be undervalued.
The stock's Bollinger Band range is $79.90 to $135.21, and it is currently trading way below the bottom of the band.
The stock may retrace near its Friday low and then take off, with potential resistance at $70 and $74.

Generated by AI

Community

Of the messages about DXCM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	29.38%	29.79%	30.63%
Newcomers	—	70.62%	70.21%	69.37%

Regulars· Jul 31

DexCom reported strong Q2 2026 results, exceeding expectations across the board, with adjusted EPS of $0.70 and revenue of $1.31 billion.
The company's profitability improved, with non-GAAP gross margin expanding to 64.1% and operating margin increasing to 24.3%.
DexCom reaffirmed full-year 2026 revenue guidance of $5.18 billion to $5.25 billion and maintained a positive outlook on profitability, with the company also benefiting from its $1 billion share repurchase program.

Newcomers· Jul 23

NovaRed's amended option agreement marks another major expansion of the Wilmac Project, adding 5 mineral tenures and increasing the project size to approximately 16,078 hectares.
The Wilmac Project now spans a larger area, with NovaRed's strategic planning and measured growth enabling the company to expand its land package and exploration potential.
The project's increased size and added mineral tenures are expected to provide more optionalities for NovaRed, allowing the company to continue growing its land package and exploring for copper.

Generated by AI

Market Overview Stocks began their breakout to new all-time highs again, but it remains a highly selective environment. Only the Nasdaq hit a record high, as it finished up 2.06% on the week, and outperformed for the

1d agoBenzinga

DexCom (DXCM) Stock Looks Cheap Based On Future Cash Flow

DexCom shares have delivered a mixed ride in recent years, and that uneven path raises a simple question for anyone looking at the chart today. Is the current US$87.47 price adequately supported by the cash the business is expected to generate over time? Over the past 5 years the stock has declined 36.0%, which puts the focus squarely on whether the cash flow story still lines up with the share price. The recent move to expand Jereme Sylvain’s remit to Chief Operating Officer as well as...

5d agoYahoo Finance

Is DexCom (DXCM) Cheap After Its Leadership Reshuffle Or Already Fairly Priced?

DexCom (DXCM) just reshuffled its leadership team, with longtime finance chief Jereme Sylvain stepping into a combined EVP and Chief Operating Officer role that now includes responsibility for global operations and quality. Recent boardroom moves at DexCom have arrived at a time when the 90-day share price return of 27.79% and year-to-date gain of 31.85% point to building momentum. However, the 1-year total shareholder return of 29.97% contrasts with a weaker 3-year record and a deeper 5-year...

6d agoYahoo Finance

DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer

DexCom (NasdaqGS:DXCM) has promoted former Chief Financial Officer Jereme Sylvain to EVP and Chief Operating Officer. Healthcare executive Glenn S. Boehnlein has joined DexCom's board of directors, adding external industry experience to governance. The leadership shift, including Sylvain's promotion and Boehnlein's board appointment, deserves weighing alongside DexCom's broader fundamentals and risks. Take a look at 3 other big wins we have identified for DexCom. For readers looking to...

6d agoYahoo Finance

DexCom Inc. stock underperforms Wednesday when compared to competitors

6d agoMarketWatch

Also Discussed

Investors talking about DXCM also mention

#	Name	Attention
1	Insulet CorporationPODD	0%new
2	Tandem Diabetes Care, Inc.TNDM	0%new
3	Medtronic plcMDT	0%+0
4	Nemaura Medical Inc.NMRD	0%new
5	Abbott LaboratoriesABT	0%-0.03
6	Senseonics Holdings, Inc.SENS	0%+0
7	Edwards Lifesciences CorporationEW	0%new
8	SiTime CorporationSITM	0.01%-0.07
9	Atlassian Corporation Class A Common StockTEAM	0%+0
10	HZNP - Horizon Therapeutics Public Limited Company	——

DexCom Inc.

Healthcare
Medical Devices

DexCom Inc. is a medical device company focused on continuous glucose monitoring systems for diabetes and metabolic health. Dexcom develops wearable biosensors, transmitters, receivers, and software that provide real-time glucose readings, trend data, and alerts to help users and clinicians monitor glucose levels without routine fingerstick testing. Its current product lineup includes Dexcom G7, Dexcom G7 15 Day, Dexcom G6, Dexcom ONE+, Stelo, Dexcom Share, and Dexcom Follow, along with digital tools and remote monitoring features that support daily diabetes management. The company serves people with diabetes, adults with prediabetes and type 2 diabetes who do not use insulin, and healthcare professionals across the United States and international markets. Headquartered in San Diego, California, DexCom plays a significant role in the diabetes care technology market through its focus on connected glucose sensing and data-sharing solutions.

Website

Location

6340 Sequence Drive

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about DXCM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% -0.01	0% 0

Aug 12

DexCom, Inc. (DXCM) has seen a significant increase in its stock price, with a 25.1% rise since insiders were selling three weeks ago.
The stock has cleared the 200-week moving average and is part of a sector that is starting to warm up.
DXCM has printed a new 52-week high and is expected to continue its upward trend, potentially due to an upcoming announcement from CMS, HHS, or another relevant agency.

Generated by AI

Sentiment

Of the messages about DXCM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	16.67% -58.33	33.33% -58.89	80.81% +17.85
Bearish	—	83.33% +58.33	66.67% +58.89	19.19% -17.85

Bullish· Jun 6

DexCom, Inc. is a stock that may rise according to a blogger with accurate analysis and predictions.
Following this blogger's advice can potentially lead to making $6,000 every two weeks.
The blogger has a track record of making money for their followers with their stock recommendations.

Bearish· Apr 21

$DXCM's production quality has been subpar, contributing to its poor performance.
The company's recent leadership changes, specifically the new CEO's public relations efforts, have been ineffective and may be a sign of underlying issues.
$DXCM's stock price has been declining, with weak volume and a lack of interest from investors, suggesting a bearish trend that may continue.

Generated by AI

Topics

Of the messages about DXCM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	64.29%	46.55%	19.09%
Announcements	—	28.57%	25.86%	14.03%
Analysts	—	0%	13.79%	30.71%
Earnings	—	7.14%	1.72%	3.65%
Macro	—	0%	12.07%	32.26%
Controversies	—	0%	0%	0.26%

Earnings· Jul 30

DexCom reported Q2 2026 earnings with revenue of $1.31B, beating estimates by +2% YoY, and adjusted EPS of $0.70, beating estimates by +15% YoY.
The company raised its FY26 revenue guidance to $5.18-$5.25B, with operating margin guided to 23.5-24%, and non-GAAP operating income of $328.3M, beating estimates by +15% YoY.
DexCom's Q2 2026 results showed a +13% YoY revenue growth, with adjusted EBITDA of $421.3M, beating estimates by +9% YoY, and a non-GAAP operating margin of 24.3%, a +590bps YoY increase.

Analysts· Oct 29

Oppenheimer raised DexCom's price target to $625 with an outperform rating.
Multiple analysts, including Canaccord, Piper Sandler, and SVB Leerink, raised DexCom's price target, with some targets exceeding $675.
Analysts at firms such as Morgan Stanley, Jefferies Financial Group, and Robert W. Baird also raised DexCom's price target, with Morgan Stanley maintaining an equal weight rating.

Announcements· Jul 23

NovaRed expanded the Wilmac project to approximately 16,078 hectares through its amended agreement, increasing its land position and future exploration potential.
The company continues to grow its land package through measured expansion and strategic planning, with the latest addition of 5 mineral tenures and 4,573.82 hectares.
NovaRed's amended option agreement marks another major growth of the Wilmac Project, increasing its size to approximately 16,078 hectares and its exploration potential across the project.

Technical Analysis· Jul 29

$DXCM's RSI is currently at 14, considered oversold, and may be undervalued.
The stock's Bollinger Band range is $79.90 to $135.21, and it is currently trading way below the bottom of the band.
The stock may retrace near its Friday low and then take off, with potential resistance at $70 and $74.

Generated by AI

Community

Of the messages about DXCM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	29.38%	29.79%	30.63%
Newcomers	—	70.62%	70.21%	69.37%

Regulars· Jul 31

DexCom reported strong Q2 2026 results, exceeding expectations across the board, with adjusted EPS of $0.70 and revenue of $1.31 billion.
The company's profitability improved, with non-GAAP gross margin expanding to 64.1% and operating margin increasing to 24.3%.
DexCom reaffirmed full-year 2026 revenue guidance of $5.18 billion to $5.25 billion and maintained a positive outlook on profitability, with the company also benefiting from its $1 billion share repurchase program.

Newcomers· Jul 23

NovaRed's amended option agreement marks another major expansion of the Wilmac Project, adding 5 mineral tenures and increasing the project size to approximately 16,078 hectares.
The Wilmac Project now spans a larger area, with NovaRed's strategic planning and measured growth enabling the company to expand its land package and exploration potential.
The project's increased size and added mineral tenures are expected to provide more optionalities for NovaRed, allowing the company to continue growing its land package and exploring for copper.

Generated by AI

DexCom

Social

Aug 12

Bullish· Jun 6

Bearish· Apr 21

Earnings· Jul 30

Analysts· Oct 29

Announcements· Jul 23

Technical Analysis· Jul 29

Regulars· Jul 31

Newcomers· Jul 23

Why DexCom Could Be the Big Winner Out of Oura’s IPO

The Insider Report: The Leaders Have Taken Off - DexCom (NASDAQ:DXCM), Zai Lab (NASDAQ:ZLAB)

DexCom (DXCM) Stock Looks Cheap Based On Future Cash Flow

Is DexCom (DXCM) Cheap After Its Leadership Reshuffle Or Already Fairly Priced?

DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer

DexCom Inc. stock underperforms Wednesday when compared to competitors

Also Discussed

DexCom Inc.

Company Information

Location

Why DexCom Could Be the Big Winner Out of Oura’s IPO

The Insider Report: The Leaders Have Taken Off - DexCom (NASDAQ:DXCM), Zai Lab (NASDAQ:ZLAB)

DexCom (DXCM) Stock Looks Cheap Based On Future Cash Flow

Is DexCom (DXCM) Cheap After Its Leadership Reshuffle Or Already Fairly Priced?

DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer

DexCom Inc. stock underperforms Wednesday when compared to competitors

Also Discussed

Social

Aug 12

Bullish· Jun 6

Bearish· Apr 21

Earnings· Jul 30

Analysts· Oct 29

Announcements· Jul 23

Technical Analysis· Jul 29

Regulars· Jul 31

Newcomers· Jul 23